MMWR News Synopsis
Friday, March 18, 2022
- Tobacco Product Use Among Adults — United States, 2020
- Progress Toward Achieving and Sustaining Maternal and Neonatal Tetanus Elimination — Worldwide, 2000–2020
- Reported Cases of End-Stage Kidney Disease — United States, 2000–2019
- The Advisory Committee on Immunization Practices’ Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines — United States, February 2022
- Previously Released Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022
- Previously Released Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022
- Quick Stats
Articles
Tobacco Product Use Among Adults — United States, 2020
CDC Media Relations
404-639-3286
From 2019 to 2020, the use of commercial tobacco products overall, combustible tobacco products, cigarettes, e-cigarettes, and multiple tobacco products (two or more), decreased among U.S. adults. However, in 2020, nearly 1 in 5 adults (an estimated 47.1 million) used tobacco products. The 2020 National Health Interview Survey assessed current commercial tobacco product use among U.S. adults aged 18 or older. CDC analyzed these data and found that in 2020, 19.0% of U.S. adults used at least one tobacco product, down from 20.8% in 2019. Cigarettes were the most commonly used product (12.5%), followed by e-cigarettes (3.7%). While adult cigarette smoking declined to its lowest level recorded since 1965, an estimated 30.8 million adults reported smoking cigarettes in 2020. More than three-fourths of adults who currently used tobacco products in 2020 used combustible products. Cigarettes and other combustible tobacco products are the predominant cause of tobacco-related disease, disability, and death Increasing the use of evidence-based commercial tobacco control interventions can help prevent people from starting tobacco product use and help people quit, further reducing tobacco use and related diseases. Continued monitoring of tobacco use, and tailored strategies and policies that reach populations with high rates of tobacco use, could further aid in reducing disparities in tobacco product use.
Progress Toward Achieving and Sustaining Maternal and Neonatal Tetanus Elimination — Worldwide, 2000–2020
CDC Media Relations
404-639-3286
From 2000 to 2020, reported tetanus cases among newborns decreased worldwide by 88% and estimated deaths decreased by 92%. Despite this progress, infants in 12 countries still face a deadly threat from maternal and neonatal tetanus. Neonatal tetanus is almost always fatal but can be prevented when mothers are fully vaccinated before giving birth and skilled birthing attendants assist with hygienic deliveries. By December 2020, 168 million of the 250 million women of reproductive age who were living in high-risk areas received at least two doses of tetanus toxoid-containing vaccine. Infants protected at birth against tetanus increased from 74% in 2000 to 86% in 2020, and 47 of the 59 priority countries were validated to have achieved maternal and neonatal tetanus elimination (MNTE). There are 12 countries that have not achieved MNTE. To achieve and sustain elimination, priority countries should enhance routine vaccinations across the lifespan, increase hygienic deliveries by skilled birthing attendants, and strengthen surveillance of neonatal tetanus.
Reported Cases of End-Stage Kidney Disease — United States, 2000–2019
CDC Media Relations
404-639-3286
Kidney failure requiring dialysis or transplantation, or end-stage kidney disease, will continue to have a major impact on the U.S. health care system. Reasons include the growth of the U.S. population, aging, improved survival of kidney failure patients, and high occurrence of risk factors such as diabetes. Continued efforts to improve diabetes care and management of risk factors for kidney failure (e.g., high blood pressure and protein in the urine) may stabilize and eventually reverse the growth in new cases of kidney failure in the United States. From 2000 to 2019, the number of reported cases of end-stage kidney disease (ESKD) continued to increase in the United States. Although the total number of people with ESKD will continue to increase with better survival of the population being treated for kidney failure and improved transplant outcomes, better management of risk factors for kidney failure (e.g., high blood pressure and protein in the urine) in people with diabetes may slow and eventually reverse the growth in the number of new kidney failure cases. Continued efforts to prevent or delay kidney failure and improve management of patients, in addition to increasing kidney transplantation, will continue to impact these trends. Management interventions include the use of therapeutic agents such as angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and sodium-glucose cotransporter 2 inhibitors shown to have kidney protective benefits might slow the increase and eventually reverse the trend in incident ESKD cases.
The Advisory Committee on Immunization Practices’ Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines — United States, February 2022
CDC Media Relations
404-639-3286
This report details recommendations from the Advisory Committee on Immunization Practices (ACIP) for use of the Moderna COVID-19 vaccine in people ages 18 years and older. After more than 12 months under FDA emergency use authorization and an interim ACIP recommendation, the Moderna COVID-19 vaccine now has full FDA approval and a standard recommendation by ACIP for continued use in people ages 18 years and older.
Previously Released Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022
CDC Media Relations
404-639-3286
Previously Released Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022
CDC Media Relations
404-639-3286
- Content
###
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
CDC works 24/7 protecting America’s health, safety and security. Whether diseases start at home or abroad, are curable or preventable, chronic or acute, or from human activity or deliberate attack, CDC responds to America’s most pressing health threats. CDC is headquartered in Atlanta and has experts located throughout the United States and the world.